CHRYSALIS Exploratory Analysis: Molecular Responses With FLT3/AXL Inhibitor Gilteritinib in Relapsed/Refractory < i > FLT3 < /i > -ITD AML

Slideset - Study investigators conclude that molecular response may predict durable clinical benefit in patients treated with gilteritinib.

Source: Clinical Care Options Leukemia - June 14, 2017 Category: Hematology Source Type: research